CME in Minutes: Education in Ophthalmology

Please visit answersincme.com/ADC860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jordana Goren Fein, MD, MS. In this activity, an expert in retinal vein occlusion (RVO) reviews diagnostic best practices, newer-generation anti-VEGF therapies, and patient-centered management strategies. Upon completion of this activity, participants should be better able to: Describe best practices for diagnosing RVO; Differentiate between the clinical profiles of available newer-generation intravitreal anti-VEGF therapies for macular edema (ME) secondary to RVO; and Propose optimized, patient-centered treatment plans for the multidisciplinary management of patients with RVO.

Please visit answersincme.com/AGN860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Ferhina Ali, MD, MPH, FASRS. In this activity, an expert in retinal diseases discusses anti-VEGF treatment of diabetic macular edema. Upon completion of this activity, participants should be better able to: Recognize factors that contribute to patients' treatment burden with intravitreal anti–vascular endothelial growth factor (VEGF) therapies for diabetic macular edema (DME); Assess the clinical profiles of long-acting intravitreal anti-VEGF agents for DME; and Recommend individualized strategies to enhance long-term treatment outcomes for patients with DME.

Please visit answersincme.com/YMM860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Nitish Mehta, MD; and Sarwar Zahid, MD. In this activity, experts in diabetic retinopathy discuss long-acting anti-VEGF agents and strategies to improve outcomes for patients with diabetic macular edema (DME). Upon completion of this activity, participants should be better able to: Recognize factors that contribute to patients' treatment burden with intravitreal anti-VEGF therapies for diabetic macular edema (DME); Assess the clinical profiles of long-acting intravitreal anti-VEGF agents for DME; and Recommend individualized strategies to enhance long-term treatment outcomes for patients with DME.

Please visit answersincme.com/RTS860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, a pediatrician and a pediatric dermatologist discuss strategies for optimizing biologic treatment for moderate to severe atopic dermatitis (AD). Upon completion of this activity, participants should be better able to: Recognize when treatment escalation to systemic therapy is warranted in pediatric patients with atopic dermatitis (AD); Select the optimal biologic for a given pediatric patient with moderate to severe AD; and Outline strategies to optimize biologic treatment in pediatric patients with moderate to severe AD. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/SYV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in retinal vein occlusion (RVO) discuss diagnosis and anti-VEGF treatment of the condition. Upon completion of this activity, participants should be better able to: Explain the rationale for exploring longer-acting anti-VEGF treatment for patients with RVO; Recognize the importance of early diagnosis to address the burden of RVO; and Propose optimized, patient-centered treatment plans for the multidisciplinary management of patients with RVO.